Abstract: Ionizable cationic lipid compounds have an amine moiety from amino alcohols and a lipid moiety from a lipid synthesized via esterification. The ionizable cationic lipid compounds which comprise an amino alcohol mediated ionizable cationic lipid compound are useful for in vivo or in vitro delivery of one or more nucleic acid agents including DNA, siRNA, a microRNA, an mRNA, a RNAi, and a plasmid.

Abstract: A method is disclosed. The method comprises receiving, from a server computer, a challenge, and displaying objects from an object list to a user. The method includes determining that a user has visually selected an object from the object list and moving the selected object on a display according to screen coordinates. A client computer captures a biometric of the user, and compares the biometric to another biometric stored in the client computer to provide a first comparison output, and compares a derivative of the selected object to a derivative of an object stored in the client computer to produce a second comparison output. The client computer signs the challenge with a private key and sends the signed challenge to the server computer, and the server computer verifies the signed challenge.

Abstract: A transcription of audio speech included in electronic content associated with a meeting is created by an ASR model trained on speech-to-text data. The transcription is post-processed by modifying text included in the transcription, for example, by modifying punctuation, grammar, or formatting introduced by the ASR model and by changing or omitting one or more words that were included in both the audio speech and the transcription. After the transcription is post-processed, output based on the post-processed transcription is generated in the form of a meeting summary and/or template.

Abstract: A data platform for developing and deploying a user application within a unified security context. The data platform authorizes a first user to use an editor to access source code of a user application based on security policies of a security context and authorizes the first user to use an application and data manager to set usage privileges for a second user to use the user application based on the security policies of the security context. To provide the user application to the second user, the data platform deploys the user application by instantiating a User Defined Function (UDF) server and an application engine of the UDF server within the security context, instantiating the user application as an application of the application engine within the security context, and authorizing access by the user application to databased on the security policies of the security context.

Abstract: A copy of a model comprising a plurality of trees is received, as is a copy of training set data comprising a plurality of training set examples. For each tree included in the plurality of trees, the training set data is used to determine which training set examples are classified as a given leaf. A blame forest is generated at least in part by mapping each training set item to the respective leaves at which it arrives.

Abstract: Provided herein are methods and compositions for treating von Willebrand disease with platelets, platelet derivatives, and/or thrombosomes.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: An optical system (31) for analysing biological processes comprising: a biological process vessel (33) comprising a chamber and an optical interface element (34) for optically coupling the chamber to an optical emitter, a wavelength discrimination component, and an optical detector when a biological process fluid in the chamber is being analysed, the optical interface element being configured to couple light in the mid-infrared range; an optical emitter (351) configured to emit light in the mid-infrared range; an optical detector (353) configured to detect light in the mid-infrared range; a wavelength discrimination component (352); an alignment component (42) for aligning the optical emitter, optical detector, and wavelength discrimination component with the optical interface element; and a processor (354) configured to: receive outputs from the optical detector; and process the received outputs from the optical detector to provide an indication of the constituents of a biological process fluid in the chambe

Abstract: Embodiments described herein provide a semiconductor package comprising multiple dies encapsulated in multiple molding compounds. In one example, a semiconductor package comprises: a first die or die stack on a substrate; a first molding compound encapsulating the first die or die stack on the substrate; a second die or die stack on the first molding compound; and a second molding compound encapsulating the second die or die stack and at least one portion of the first molding compound. In this example, the first die or die stack is electrically coupled to the substrate using a first wire bond and the second die or die stack is electrically coupled to the substrate using a second wire bond. Additionally, the first molding compound encapsulates the first wire bond and the second molding compound encapsulates the second wire bond. Furthermore, a footprint of the second die overlaps a footprint of the first die.

Abstract: The present disclosure relates to indolinyl compounds. The present disclosure further relates to compounds that inhibit viral helicase-primase. The present disclosure further relates to the use of the compounds for the preparation a medicament for the treatment of diseases and/or condition through inhibiting viral helicase-primase. The present disclosure also relates to use of those compounds in the treatment of viral infections. The present disclosure further relates to intermediates for its preparation and to pharmaceutical compositions containing those compounds.

Abstract: In accordance with various embodiments of the present disclosure, a first instance of a data intake and query system (DIQS) may receive latency data that indicates latency states of second instances of the DIQS, the latency states indicative of latencies associated with processing of event data by the plurality of second instances. The first instance may then determine overall latency state of the first instance based, at least in part, on determining number or percentage of the first instance and the second instances of the DIQS having one or more particular latency states, and determining whether the number or percentage of the first instance and the f second instances of the DIQS having the one or more particular latency states is equal to or exceeds a threshold. The first instance may then present the overall latency state of the first instance.

Abstract: A slot type game with one or more dynamic paylines and/or dynamic payline modifiers includes a grid or matrix of symbols for which one or more symbol outcomes may be determined and presented. In embodiments with a dynamic payline, the slot type game also includes a payline determination for which a payline outcome may be determined and presented. The payline outcome may correspond to positions of symbols in the grid or matrix and may determine whether or not the corresponding symbols in the grid or matrix are winners. In embodiments with a dynamic payline modifier, the slot type game also includes a payline modifier for which a payline modifier outcome may be determined and presented. The payline modifier outcome may correspond to positions of symbols in one or more paylines and may determine whether or not the one or more paylines and/or symbols are modified.

Abstract: A package comprising a first metallization portion, a first integrated device coupled to the first metallization portion through a first plurality of pillar interconnects, and a first chiplet located between the first integrated device and the first metallization portion. The first chiplet is coupled to the first integrated device through a first plurality of inter pillar interconnects. The first chiplet may include an active chiplet. The first chiplet may include a passive chiplet.

Abstract: A package comprising a first metallization portion, a first integrated device coupled to the first metallization portion, a second integrated device coupled to the first metallization portion, a second metallization portion coupled to the first metallization portion through a first plurality of pillar interconnects, a first chiplet located between the first metallization portion and the second metallization portion, wherein the first chiplet is configured to be electrically coupled to the first integrated device through the first metallization portion, and a second chiplet located between the first metallization portion and the second metallization portion, wherein the second chiplet is configured to be electrically coupled to the second integrated device through the first metallization portion.

Abstract: In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.

Abstract: A secure hardware-based module or Security Electronic Control Unit (SECU) for a Controller Area Network (CAN) prevents an attacker from sending malicious messages through the CAN bus to take over control of a vehicle. The SECU shares a unique key and counter with each ECU on the CAN bus. When a legitimate ECU sends a message, it first compresses the message and then generates a MAC of the counter and a secret key. The counter is increased by one for each transmitted message. The ECU then fits the compressed message and the MAC into one CAN frame and sends it onto the CAN bus. The SECU performs the message verification on behalf of the intended receiver(s) of the message. If the verification passes, the receiver(s) simply decompress the message and use it as a normal CAN message. If the verification fails, the SECU will corrupt the CAN frame before it is fully received by the intended receiver(s). The corrupted CAN frame will be ignored by the intended receiver(s) as if it was never received.

Abstract: A secure hardware-based module or Security Electronic Control Unit (SECU) for a Controller Area Network (CAN) prevents an attacker from sending malicious messages through the CAN bus to take over control of a vehicle. The SECU shares a unique key and counter with each ECU on the CAN bus. When a legitimate ECU sends a message, it first compresses the message and then generates a MAC of the counter and a secret key. The counter is increased by one for each transmitted message. The ECU then fits the compressed message and the MAC into one CAN frame and sends it onto the CAN bus. The SECU performs the message verification on behalf of the intended receiver(s) of the message. If the verification passes, the receiver(s) simply decompress the message and use it as a normal CAN message. If the verification fails, the SECU will corrupt the CAN frame before it is fully received by the intended receiver(s). The corrupted CAN frame will be ignored by the intended receiver(s) as if it was never received.